Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | WHR1 | P49842 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406751 | 0.79 | KDM4E (0.47) | — | |
| SCHEMBL8239788 | 0.76 | MGLL (0.43) | MGLLMAOBPDE10AHDAC4WHR1 | |
| SCHEMBL8239786 | 0.75 | PDE10A (0.45) | MGLLMAOBPDE10AGBA1 | |
| SCHEMBL4416479 | 0.70 | CYP19A1 (0.38) | MAOBPDE10A | |
| SCHEMBL3641349 | 0.67 | MAOB (0.57) | MAOBCNR2HTR6 | |
| SCHEMBL21957634 | 0.66 | HDAC4 (0.54) | MGLLMAOBHDAC4 | |
| SCHEMBL4406863 | 0.65 | MAPK1 (0.44) | MAOBHDAC4 | |
| SCHEMBL22144604 | 0.65 | GLA (0.68) | MAOBWHR1HTR6GBA1 | |
| SCHEMBL4408162 | 0.65 | GBA1 (0.37) | MGLLMAOBPDE10AHDAC4CNR2 | |
| SCHEMBL19692918 | 0.65 | KDM4E (0.39) | MAOBPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | claimed |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | MGLL 1203/4885MAOB 3001/4885PDE10A 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.